keyword
MENU ▼
Read by QxMD icon Read
search

Onabotulinumtoxina

keyword
https://www.readbyqxmd.com/read/28329903/-headache-treatment
#1
Hans Christoph Diener, Dagny Holle-Lee, Steffen Nägel, Charly Gaul
A precondition for the successful treatment of headaches is the correct headache diagnosis. Triptans are effective for attack treatment of migraine and cluster headache. However, there are not effective for the treatment of tension-type headache. For the prevention of frequent episodic migraine betablockers, flunarizine, topiramate and amitriptyline are recommended. For the prevention of chronic migraine evidence is only available for onabotulinumtoxinA and topiramate. For prophylactic treatment of tension-type headaches tricyclic antidepressants are used...
March 2017: Deutsche Medizinische Wochenschrift
https://www.readbyqxmd.com/read/28286067/future-directions-of-research-and-care-for-urinary-incontinence-in-women-findings-from-the-national-institute-of-diabetes-and-digestive-and-kidney-diseases-niddk-summit-on-urinary-incontinence-clinical-research-in-women
#2
REVIEW
Toby C Chai, Tirsit S Asfaw, Jan E Baker, Becky Clarkson, Pamela Coleman, Susan Hoffstetter, Kimberly Konkel, Missy Lavender, Shailaja Nair, Jenna Norton, Leslee Subak, Anthony Visco, Robert A Star, Tamara Bavendam
PURPOSE: Female urinary incontinence (UI) is prevalent, costly, and morbid. Participants in an NIDDK-sponsored summit reviewed findings from NIH-funded clinical research in UI and discussed the future of UI research. MATERIALS AND METHODS: On March 14 2014, the NIDDK convened a "Summit on Urinary Incontinence Clinical Research in Women." Participants representing a broad range of clinical expertise reviewed completed, NIH-sponsored UI-related studies, including results from community-based, epidemiologic studies such as the Boston Area Community Health (BACH) Survey and from randomized clinical trials such as the Program to Reduce Incontinence by Diet and Exercise (PRIDE) and studies conducted by the Pelvic Floor Disorders Network (PFDN) and the Urinary Incontinence Treatment Network (UITN)...
March 9, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28286053/onabotulinumtoxina-for-lower-limb-spasticity-guidance-from-a-delphi-panel-approach
#3
Alberto Esquenazi, Abraham Alfaro, Ziyad Ayyoub, David Charles, Khashayar Dashtipour, Glenn D Graham, John R McGuire, Ib R Odderson, Atul T Patel, David M Simpson
BACKGROUND: OnabotulinumtoxinA is approved for the treatment of upper and lower limb spasticity in adults. Guidance on common postures and onabotulinumtoxinA injection paradigms for upper limb spasticity has been developed using a Delphi Panel. However, similar guidance for lower limb spasticity has not been established. OBJECTIVE: To define a clinically recommended treatment paradigm using onabotulinumtoxinA for each common posture among patients with post-stroke lower-limb spasticity (PSLLS); to identify the most common PSLLS aggregate postures...
March 7, 2017: PM & R: the Journal of Injury, Function, and Rehabilitation
https://www.readbyqxmd.com/read/28267602/management-of-urinary-incontinence-following-sub-urethral-sling-removal
#4
Nirmish Singla, Himanshu Aggarwal, Jeannine Foster, Feras Alhalabi, Gary E Lemack, Philippe E Zimmern
PURPOSE: To evaluate urinary incontinence outcomes following synthetic sub-urethral sling removal (SSR) in women. METHODS: We reviewed a prospectively-maintained database of 360 consecutive women who underwent transvaginal SSR from 2005-2015. We excluded patients with neurogenic bladder, non-synthetic or multiple slings, prior mesh for prolapse, concomitant surgery during sling excision, urethral erosion or fistula, post-operative retention, or <6 months follow-up...
March 3, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28265323/bladder-and-bowel-dysfunction-in-children-an-update-on-the-diagnosis-and-treatment-of-a-common-but-underdiagnosed-pediatric-problem
#5
REVIEW
Joana Dos Santos, Roberto I Lopes, Martin A Koyle
Bladder and bowel dysfunction (BBD) describes a spectrum of lower urinary symptoms (LUTS) accompanied by fecal elimination issues that manifest primarily by constipation and/or encopresis. This increasingly common entity is a potential cause of significant physical and psychosocial burden for children and families. BBD is commonly associated with vesicoureteral reflux (VUR) and recurrent urinary tract infections (UTIs), which at its extreme may lead to renal scarring and kidney failure. Additionally, BBD is frequently seen in children diagnosed with behavioural and neuropsychiatric disorders such as attention-deficit/hyperactivity disorder (ADHD) and autism spectrum disorder (ASD)...
January 2017: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/28262756/urodynamic-prognostic-factors-for-large-post-void-residual-urine-volume-after-intravesical-injection-of-onabotulinumtoxina-for-overactive-bladder
#6
Sheng-Mou Hsiao, Ho-Hsiung Lin, Hann-Chorng Kuo
The aim of this study was to identify factors predicting large post-void residual (PVR) (defined as ≥200 mL), an important unsolved problem, after an intravesical injection of onabotulinumtoxinA in patients with overactive bladder syndrome. The data showed that 133 of 290 patients had a large PVR after treatment. Multivariate analysis found that the baseline 3-day daytime frequency episodes and voiding efficiency were independent predictors for postoperative large PVR. A receiver operating characteristic (ROC) curve analysis showed the following optimum cut-off values: (1) 3-day daytime frequency episodes = 25, which has a ROC area of 0...
March 6, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28261683/botox-combined-with-myofascial-release-physical-therapy-as-a-treatment-for-myofascial-pelvic-pain
#7
Gabriela E Halder, Lauren Scott, Allison Wyman, Nelsi Mora, Branko Miladinovic, Renee Bassaly, Lennox Hoyte
PURPOSE: To report the effects of combined onabotulinumtoxinA (Botox) injections and myofascial release physical therapy on myofascial pelvic pain (MFPP) by comparing pre- and posttreatment average pelvic pain scores, trigger points, and patient self-reported pelvic pain. Secondary outcomes were to examine posttreatment complications and determine demographic differences between patients with/without an improvement in pain. MATERIALS AND METHODS: This was an Institutional Review Board approved retrospective case series on women over 18 years with MFPP who received Botox and physical therapy between July 2006 and November 2014...
March 2017: Investigative and Clinical Urology
https://www.readbyqxmd.com/read/28249800/re-onabotulinumtoxina-vs-sacral-neuromodulation-on-refractory-urgency-urinary-incontinence-in-women-a-randomized-clinical-trial
#8
Jean-Nicolas Cornu
No abstract text is available yet for this article.
February 26, 2017: European Urology
https://www.readbyqxmd.com/read/28248698/extracranial-origin-of-headache
#9
Rami Burstein, Pamela Blake, Aaron Schain, Carlton Perry
PURPOSE OF REVIEW: To summarize recent clinical and preclinical studies on extracranial pathophysiologies in migraine. It challenges the opinion-based notion that the headache phase of migraine occurs without input from peripheral nociceptors or is caused solely by activation of intracranial nociceptors supplying dural and cerebral vasculature. RECENT FINDINGS: Data that support a scenario by which migraine can originate extracranially include the perception of imploding headache that hurts outside the cranium, the existence of a network of sensory fibers that bifurcate from parent axons of intracranial meningeal nociceptors and reach extracranial tissues such as periosteum and pericranial muscles by crossing the calvarial bones through the sutures, the discovery of proinflammatory genes that are upregulated and anti-inflammatory genes that are down regulated in extracranial tissue of chronic migraine patients, and evidence that administration of OnabotulinumtoxinA to peripheral tissues outside the calvaria reduces frequency of migraine headache...
March 14, 2017: Current Opinion in Neurology
https://www.readbyqxmd.com/read/28213829/onabotulinumtoxina-effectiveness-on-chronic-migraine-negative-emotional-states-and-sleep-quality-a-single-center-prospective-cohort-study
#10
Elif Ilgaz Aydinlar, Pinar Yalinay Dikmen, Seda Kosak, Ayse Sagduyu Kocaman
BACKGROUND: OnabotulinumtoxinA (OnabotA) is considered effective in in patients with chronic migraine (CM) who failed on traditional therapies. This study was designed to evaluate the effect of OnabotA injection series on migraine outcome, negative emotional states and sleep quality in patients with CM. METHODS: A total of 190 patients with CM (mean (SD) age: 39.3 (10.2) years; 87.9% were female) were included. Data on Pittsburgh sleep quality index (PSQI), headache frequency and severity, number of analgesics used, Migraine Disability Assessment Scale...
December 2017: Journal of Headache and Pain
https://www.readbyqxmd.com/read/28202358/a-prospective-multicenter-double-blind-randomized-trial-of-bladder-instillation-of-liposome-formulation-onabotulinumtoxina-for-interstitial-cystitis-bladder-pain-syndrome
#11
Yao-Chi Chuang, Hann-Chorng Kuo
BACKGROUND: Intravesical instillation of liposomal-formulated botulinum toxin A (lipotoxin) has shown therapeutic effects on treatment of refractory overactive bladder without needle injections. We hereby assessed lipotoxin for the treatment of refractory interstitial cystitis/bladder pain syndrome (IC/BPS). METHODS: This two-center, double-blind, randomized, placebo-controlled physician-initiated study enrolled patients with refractory IC/BPS. The patients were assigned to intravesical instillation of lipotoxin (onabotulinumtoxinA 200 U with 80mg sphingomyelin) (n=31), onabotulinumtoxinA 200 U in normal saline (n=28), or normal saline alone (n=31)...
February 12, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28196743/onabotulinumtoxina-in-urinary-incontinence-prospective-study-of-a-case-series
#12
A Martín-Martínez, A Fernández-Mederos, J Á García-Hernández
OBJECTIVE: To assess the safety and efficacy of a single intravesical injection of onabotulinumtoxinA (OnaBTA) for treating urge urinary incontinence (UUI) in women. METHOD: We performed a prospective case-series study of consecutive patients with refractory UUI treated with an intravesical injection of OnaBTA. The patients were administered 100 units of OnaBTA injected into the bladder wall following 4 weeks of flushing with anticholinergic agents or beta 3 agonists...
February 10, 2017: Actas Urologicas Españolas
https://www.readbyqxmd.com/read/28170477/onabotulinumtoxina-vs-sacral-neuromodulation-for-urgency-incontinence-reply
#13
LETTER
Cindy L Amundsen, Holly E Richter, Dennis Wallace
No abstract text is available yet for this article.
February 7, 2017: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/28170474/onabotulinumtoxina-vs-sacral-neuromodulation-for-urgency-incontinence
#14
LETTER
John F McCauley, Hector M Gonzalez, David James Osborn
No abstract text is available yet for this article.
February 7, 2017: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/28170473/onabotulinumtoxina-vs-sacral-neuromodulation-for-urgency-incontinence
#15
LETTER
Bertil F M Blok
No abstract text is available yet for this article.
February 7, 2017: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/28161352/the-efficacy-and-safety-of-onabotulinumtoxina-or-solifenacin-compared-with-placebo-in-solifenacin-na%C3%A3-ve-patients-with-refractory-overactive-bladder-results-from-a-multicenter-randomized-double-blind-phase-3b-trial
#16
Sender Herschorn, Alfred Kohan, Philip Aliotta, Kurt McCammon, Rajagopalan Sriram, Steven Abrams, Wayne Lam, Karel Everaert
PURPOSE: This double-blind, randomized study compared the efficacy/safety of onabotulinumtoxinA or solifenacin versus placebo in overactive bladder patients with urinary incontinence who had an inadequate response to/were intolerant of an anticholinergic. A post-hoc analysis compared effects of onabotulinumtoxinA versus solifenacin. MATERIALS AND METHODS: Solifenacin-naïve patients were randomized to onabotulinumtoxinA 100U, solifenacin 5mg (could escalate to 10mg at week 6 with predefined criteria), or placebo...
February 1, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28139068/positive-outcomes-with-first-onabotulinumtoxina-treatment-persist-in-the-long-term-with-repeat-treatments-in-patients-with-neurogenic-detrusor-overactivity
#17
Pierre Denys, Roger Dmochowski, Philip Aliotta, David Castro-Diaz, Bertil Blok, Karen Ethans, Tamer Aboushwareb, Andrew Magyar, Michael Kennelly
OBJECTIVE: To examine whether response to first treatment with onabotulinumtoxinA is predictive of long-term treatment outcome in patients with neurogenic detrusor overactivity (NDO). PATIENTS AND METHODS: Patients with NDO who were enrolled in a 3-year extension study (after a 52-week phase III study) received onabotulinumtoxinA 'as needed', based on fulfilment of prespecified retreatment criteria. This post hoc analysis included patients who received only the 200-U dose during the phase III and extension studies...
January 31, 2017: BJU International
https://www.readbyqxmd.com/read/28118733/safety-and-efficacy-of-letibotulinumtoxina-botulax%C3%A2-in-treatment-of-post-stroke-upper-limb-spasticity-a-randomized-double-blind-multi-center-phase-iii-clinical-trial
#18
Kyung Hee Do, Min Ho Chun, Nam-Jong Paik, Yoon Ghil Park, Shi-Uk Lee, Min-Wook Kim, Don-Kyu Kim
OBJECTIVE: To investigate a new botulinum neurotoxin type A, termed letibotulinumtoxinA(Botulax(®)) and compare its efficacy and safety for post-stroke upper limb spasticity with that of onabotulinumtoxinA(Botox(®)). DESIGN: A prospective, double-blinded, multicenter, randomized controlled clinical study. SETTING: Six university hospitals in Korea. SUBJECTS: A total of 187 stroke participants with upper limb spasticity...
January 1, 2017: Clinical Rehabilitation
https://www.readbyqxmd.com/read/28089729/urinary-biomarkers-in-women-with-refractory-urgency-urinary-incontinence-randomized-to-sacral-neuromodulation-versus-onabotulinumtoxina-compared-to-controls
#19
Holly E Richter, Pamela Moalli, Cindy L Amundsen, Anna P Malykhina, Dennis Wallace, Rebecca Rogers, Deborah Myers, Maria Paraiso, Michael Albo, Haolin Shi, Tracy Nolen, Susie Meikle, R Ann Word
PURPOSE: We measured urinary biomarker levels in women with refractory urgency urinary incontinence and controls at baseline and 6 months after treatment with sacral neuromodulation or intradetrusor injection of onabotulinumtoxinA. We also assessed the association of baseline biomarkers with posttreatment urgency urinary incontinence episodes and overactive bladder symptom bother outcomes. MATERIALS AND METHODS: First morning urine samples were collected from consented trial participants and age matched women without urgency urinary incontinence...
January 13, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28012773/onabotulinumtoxina-for-the-treatment-of-patients-with-overactive-bladder-and-urinary-incontinence-results-of-a-phase-3-randomized-placebo-controlled-trial
#20
Victor W Nitti, Roger Dmochowski, Sender Herschorn, Peter Sand, Catherine Thompson, Christopher Nardo, Xiaohong Yan, Cornelia Haag-Molkenteller
PURPOSE: Overactive bladder affects 12% to 17% of the general population and almost a third experience urinary incontinence, which may severely impact health related quality of life. Oral anticholinergics are the mainstay of pharmacological treatment but they are limited by inadequate efficacy or side effects, leading to a high discontinuation rate. We report the results of the first large (557 patients), phase 3, placebo controlled trial of onabotulinumtoxinA in patients with overactive bladder and urinary incontinence inadequately managed with anticholinergics...
December 21, 2016: Journal of Urology
keyword
keyword
3072
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"